National Institute for Health and Care Excellence

23/06/2026

It’s great to see people like Patrick benefitting from dupilumab to treat COPD after we recommended the milestone drug earlier this year.

It provides an effective, targeted therapy that has shown impressive results and improves people’s quality of life.

Recommending this medicine demonstrates NICE is continuing to get the best care to patients fast while ensuring value for the taxpayer.

Learn more: https://www.nice.org.uk/news/articles/new-hope-for-people-with-breathing-condition-copd-as-nice-approves-innovative-treatment

23/06/2026

When Elena signed her 9-year-old son Dima up to the ELSA screening study, she discovered he had stage 2 type 1 diabetes.

Dima went on to receive teplizumab, a treatment that delays the onset of symptomatic type 1 diabetes.

Elena said: "As a mother, the most valuable thing teplizumab has given us is time. Every month and every year that Dima can continue being a child without insulin injections, carb counting and the daily burden of type 1 diabetes is incredibly precious.

"This recommendation means that other families across the UK may now have access to that same opportunity. Early screening and access to treatment can change the way families experience this diagnosis and help them feel prepared rather than overwhelmed."

NICE has today recommended teplizumab for NHS use. It is the first treatment that can delay the onset of type 1 diabetes by an average of nearly three years. England is the first country in Europe to make it available through a health technology appraisal.

Learn more: https://www.nice.org.uk/news/articles/teplizumab-to-delay-the-onset-of-type-1-diabetes-recommended?utm_medium=organic&utm_source=facebook&utm_campaign=teplizumab&utm_content=graphic

19/06/2026

Today is , and we want to share Jimi Olaghere's story.

Jimi spent 35 years living with sickle cell disease (the most severe form) in constant pain.

After taking part in a clinical trial for CRISPR gene therapy, everything changed. Within a week, the pain was gone for the first time in his life. He has since climbed Mount Kilimanjaro and is raising 3 children, while pursuing the career he always dreamed of.

In January 2025, NICE recommended Casgevy for use in England.

It's the first therapy using CRISPR gene editing technology to be approved by NICE, and the decision specifically recognised its potential to tackle health inequalities, as sickle cell disease disproportionately affects people from African, Caribbean, Middle Eastern, and South Asian backgrounds.

Jimi's story shows why NICE’s approval really matters.

Read Jimi's full story and find out more about NICE's guidance: https://indepth.nice.org.uk/world-sickle-cell-day/index.html

17/06/2026

A simple at-home test is preventing 140,000 unnecessary bowel cancer referrals a year.

Dr Katie Elliott is a GP and primary care clinical director at the Northern Cancer Alliance. In this guest blog, she explains how the faecal immunochemical test is transforming the bowel cancer urgent referral pathway, and what it tells us about the power of NICE guidance to drive NHS-wide change.

📖 Read Katie's story: https://www.nice.org.uk/news/blogs/how-the-faecal-immunochemical-test-is-changing-bowel-cancer-referrals-and-what-it-tells-us-about-the-power-of-nice-guidance

👉Developing or adopting healthtech? Explore support: https://www.nice.org.uk/what-nice-does/our-guidance/about-healthtech-guidance/nice-backing-the-healthtech-that-changes-lives

10/06/2026

NICE healthtech director Thomas Slater is on the panel at , exploring how innovation moves from research to real-world NHS adoption.

The session will explore how commitments in the 10 Year Health Plan and Life Sciences Sector Plan can be realised, and how all parts of the innovation ecosystem can work together to deliver better outcomes for patients.

👉Developing or adopting healthtech? Explore support: https://www.nice.org.uk/what-nice-does/our-guidance/about-healthtech-guidance

09/06/2026

This Diabetes Week 2026, we're sharing Aleix's story.

Managing her type 1 diabetes meant constant calculations, frequent blood sugar checks and saying no to activities she loved.

Then she got a hybrid closed loop device. The difference was immediate: less worry, better sleep and the freedom to truly enjoy life.

📈 Since we recommended this tech for eligible patients, NHS uptake for children and young people (a priority group) has risen from 36% to 73%.

This successful rollout is the model we want to replicate – getting life-changing medtech, diagnostics and digital products to patients who need them while reducing pressure on frontline NHS services.

👉Developing or adopting healthtech? Explore support: https://www.nice.org.uk/what-nice-does/our-guidance/about-healthtech-guidance



https://youtu.be/q2K18qy825o?si=uhcXx2pfOIF_rRd-

Aleix shares how a hybrid closed loop device transformed her type 1...

22/05/2026

1 in 7 people in the UK live with migraine, but for years many had exhausted every available treatment with little relief.

That's changing.

Since NICE recommended atogepant and rimegepant, the first migraine-prevention tablets of their kind, prescriptions have more than tripled in a year. In 2025, 22,800 people received these medicines through their GP alone.

Migraines can last days, affect work, mental health and relationships, and cost the UK economy up to £9 billion a year. These tablets work differently from older preventative treatments, targeting the chemical directly associated with migraine attacks.

🔗 Read the data story: https://www.nice.org.uk/news/articles/more-than-20-000-people-benefitting-from-innovative-migraine-pills-recommended-by-nice?utm_medium=organic&utm_source=facebook&utm_campaign=migrane_date&utm_content=graphic

19/05/2026

"No one can understand the process as well as a patient."

After surviving a heart attack at 38, Debra joined a NICE committee as a lay member and used her lived experience to help shape our guidance on digital platforms for cardiac rehabilitation, ensuring future patients can recover at home.

At NICE, the patient perspective sits at the heart of every decision we make. Debra's story is a powerful example of why the voices of patients and lay members are so important in developing guidance that truly reflects what matters to people.

Read Debra's story here 🔗 https://indepth.nice.org.uk/from-patient-to-changemaker/index.html

13/05/2026

Bringing your baby home is one of the moments new parents look forward to most.

But for families whose newborns need precautionary antibiotics, that can mean an unexpectedly longer stay in hospital.

New NICE guidance published today means that could change.

Where a baby is born after 35 weeks, is stable, feeding well and responding to treatment, they may now be able to switch from an intravenous drip to a simple liquid antibiotic and complete their course at home, with full support from their neonatal team, including training for parents and at least two follow-up appointments after leaving hospital.

The safety of this approach has been tested across nine NHS sites in England, and the evidence is clear: babies do just as well at home as in hospital. And for many families, being able to settle in at home makes a meaningful difference to those early days together.

🔗 Read the updated guidance: https://www.nice.org.uk/news/articles/nice-updates-neonatal-infection-guidance-to-allow-home-antibiotic-treatment-for-some-babies?utm_medium=organic&utm_source=facebook&utm_campaign=neonatal_infection_13may&utm_content=graphic

05/05/2026

"My treatment has completely transformed my life.”

In Dudley, an asthma clinic is catching people before they reach crisis point, diagnosing faster and making sure patients have the right treatment from the start.

One child had missed 80 days of school because of chest problems. After one clinic visit, they had a diagnosis and a plan.

Read the full story: https://indepth.nice.org.uk/my-treatment-has-completely-transformed-my-life/index.html